Tumor angiogenesis as a therapeutic target
- 21 September 2001
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 6 (19), 1005-1024
- https://doi.org/10.1016/s1359-6446(01)01939-0
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- ‘Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examplesEuropean Journal Of Cancer, 2000
- Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: A minimal model for the anti-tumoral action of suramins and suradistasJournal of Molecular Biology, 1998
- Chiroscience/BMS MMP inhibitor progressDrug Discovery Today, 1998
- Suppression of Tumor Growth with Recombinant Murine AngiostatinBiochemical and Biophysical Research Communications, 1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- The combination of antiagniogenic agents to inhibit primary tumor growth and metastasisJournal of Pediatric Surgery, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Novel non-crossresistant diaminoanthraquinones as potential chemotherapeutic agentsJournal of Medicinal Chemistry, 1992
- Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2aNew England Journal of Medicine, 1989